Conference Coverage

ZO-FAST: Immediate Zoledronic Acid Beats Delayed Tx in Early Breast Cancer

Publish date: December 8, 2011

 

FROM THE SAN ANTONIO BREAST CANCER SYMPOSIUM

Dr. de Boer is on the speakers’ bureau for Novartis. Dr. Ingle said he had no financial conflicts to disclose.

Pages

Recommended Reading

Walking Ability Aids Assessment of Elderly Breast Cancer Patients
Breast Cancer ICYMI
FDA Revokes Avastin Approval for Breast Cancer
Breast Cancer ICYMI
Practice Changers Expected at San Antonio Breast Cancer Symposium
Breast Cancer ICYMI
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
Breast Cancer ICYMI
Breast Cancer Gene Profile Identifies Early vs. Late Recurrences
Breast Cancer ICYMI
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
Breast Cancer ICYMI
IOM Dissects Environmental Risk Factors for Breast Cancer
Breast Cancer ICYMI
Dual HER2 Blockade Defers Breast Cancer Progression
Breast Cancer ICYMI
DCIS Assay Predicts Recurrence Risk After Breast Surgery
Breast Cancer ICYMI
Clodronate Offered Modest Benefit for Breast Cancer Patients
Breast Cancer ICYMI